UTILISATION CONJOINTE D'UN ANTICORPS ANTI-BCMA ET D'UN RECEPTEUR DE LYMPHOCYTES T LIE A UN ANTICORPS (ACTR) EN CANCEROTHERAPIE ET TROUBLES LIES AUX LYMPHOCYTES B
HUET, HEATHER,ETTENBERG, SETH,CHEEMA, TOOBA,HICKMAN, TAYLOR,O'CALLAGHAN, KATIE,SUSSMAN, DJANGO,RYAN, MAUREEN
申请号：
CA3053640
公开号：
CA3053640A1
申请日:
2018.02.16
申请国别(地区):
CA
年份:
2018
代理人:
摘要：
Disclosed herein are methods of enhancing antibody-dependent cell cytotoxicity (ADCC) in a subject comprising administering to a subject in need thereof a therapeutically effective amount of an anti-BCMA antibody and an effective amount of T lymphocytes and/or NK cells expressing an antibody-coupled T-cell receptor (ACTR) construct, which may comprises an extracellular domain with affinity and specific for the Fc portion of an immunoglobulin molecule (Ig)； a transmembrane domain； optionally one or more of co-stimulatory domains, and a cytoplasmic signaling domain comprising an immunoreceptor tyrosine-based activation motif (ITAM).
